Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with no effective treatments or known biomarkers for definitive diagnosis, substantiating the need for early detection and intervention. This project employs Magnetic Resonance Spectroscopy to measure neurochemical changes in the TgF344-AD rat model of AD in response to treatment with a common non-steroidal anti-inflammatory drug. Progression of neurochemical changes over time and in response to treatment are compared to behavioural measures of cognition and histopathology. Preliminary results suggest neurochemical changes are present before onset of cognitive impairment, and treatment response depends on whether treatment is administered early or late into disease progression.
This abstract and the presentation materials are available to members only; a login is required.